Clinical significance of runt- related transcription factor 1 polymorphism in prostate cancer

Abstract

Purpose: It is now well established that the most intriguing role of the runt-related transcription factors (RUNX) has emerged from the regulation of genes that are intimately associated with tumor progression, invasion, and metastasis. Given the recently highlighted RUNX1 rs2253319 in Cancer Genetic Markers of Susceptibility genome-wide association study for prostate cancer (PCa) risk, it will be interesting to investigate the association of RUNX1 following effective treatment for docetaxel refractory patients is discussed. In our department, to determine the safety and efficacy of combination chemotherapy with DT (Docetaxel and Thalidomide), DT therapy was performed on the HRPC patients who had received DEC (Docetaxel, Estramustine phosphate, and Carboplatin) therapy and had become refractory to the therapy. Materials and methods: This study included a total of 13 HRPC patients. The following schedule was used: daily Thalidomide 100-800 mg po and Docetaxel 30 mg/m2 iv on day 1, 8, and 15 of every 4-week cycle. Treatment was continued until disease progression or excessive toxicity. Results: The median patient age was 70 yr (range: 55-82). The median pretreatment PSA level was 598 ng/ml (range: 4.4-14226.1). A median of three consecutive cycles of therapy was administered per patient (range: 1-12 cycles). Of 13 patients, 12 had a PSA decline. PSA levels decreased by more than 50% in 30.8% of the patients and by more than 75% in 15.4% of the patients as a maximum response. The median rate of PSA decrease was 26.1% (range:0-93). The mean overall survival time was 7.9 months, and the median time to progression was 2.7 months. All of the patients were assessable for toxicity. Most adverse events were mild in intensity. Major toxicities related to thalidomide consisted of grade 2 somnolence and general fatigue.Conclusion: Combination chemotherapy with DOC/ Thalidomide was found to have some efficacy with an acceptable toxicity profile in HRPC patients. Further studies are necessary to evaluate clinical benefit and the adverse effects of this regimen.